Harbour BioMed Raises Additional Capital in Series A+

Harbour BioMed of Shanghai has completed a Series A+ round of unspecified size. The funding was led by CDH Investments, a China PE firm, and joined by existing investor Advantech Capital. In late 2016, Harbour was formed with $50 million in initial capital. At the same time, it acquired Harbour Antibodies BV, a Rotterdam company with two proprietary transgenic mouse platforms (see story ). The company plans to develop immuno-oncology and immunology antibodies. More details.... Share this with colleagues: // //